HAL (France)
open access
A Targeted Redox‐Active Dual‐Action Pt(IV)‐Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity
As FDA-approved platinum (Pt) anticancer drugs (e.g. cisplatin, oxaliplatin and carboplatin) grapple with clinical challenges including chemoresistance and systemic side-effects, Pt(IV) prodrugs have emerged as potent alternative chemotherapies. In this work, a novel bimetallic dual-action Pt(IV) pr
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Targeted Redox-Active Dual-Action Pt(IV)-Mn(II) Prodrug Displays Enhanced In Vivo Anticancer Activity#685934
- Multifunctional amino acid-based nanoparticles for sequential drug delivery to overcome multidrug resistant cancer#1133905
- Multidrug resistance in cancer: current understandings and future perspective.#320490
- NMR spectroscopy stability studies of Ru-IM, a prodrug candidate for triple negative breast cancer#922950
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer#880323
Record · ID 922927
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive